Filing Details
- Accession Number:
- 0001387131-16-003930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-01-20 10:33:22
- Reporting Period:
- 2016-01-19
- Filing Date:
- 2016-01-20
- Accepted Time:
- 2016-01-20 10:33:22
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1173281 | Ohr Pharmaceutical Inc | OHRP | Pharmaceutical Preparations (2834) | 465622433 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1630109 | Scott Jason Slakter | C/O Ohr Pharmaceutical Inc. 800 Third Ave., 11Th Floor New York NY 10022 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 100 | $3.92 | 859,604 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.88 | 859,804 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 500 | $3.81 | 860,304 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 400 | $3.75 | 860,704 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.73 | 860,904 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 100 | $3.70 | 861,004 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.67 | 861,204 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.66 | 861,404 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.65 | 861,604 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.60 | 861,804 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 400 | $3.59 | 862,204 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 100 | $3.57 | 862,304 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 100 | $3.56 | 862,404 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 850 | $3.55 | 863,254 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 1,200 | $3.54 | 864,454 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 1,000 | $3.53 | 865,454 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 100 | $3.52 | 865,554 | No | 4 | P | Direct | |
Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2016-01-19 | 200 | $3.52 | 865,754 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock, Par Value $0.0001 Per Share | 697,865 | Indirect | By SKS Ocular 1 LLC |
Footnotes
- SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuantto the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met and onDecember 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKSOcular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims anybeneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.